TW201718652A - 能夠結合ｂ７－ｈ３和ｃｄ３的雙特異性單價雙抗體及其用途 - Google Patents

能夠結合ｂ７－ｈ３和ｃｄ３的雙特異性單價雙抗體及其用途 Download PDF

Info

Publication number
TW201718652A
TW201718652A TW105126154A TW105126154A TW201718652A TW 201718652 A TW201718652 A TW 201718652A TW 105126154 A TW105126154 A TW 105126154A TW 105126154 A TW105126154 A TW 105126154A TW 201718652 A TW201718652 A TW 201718652A
Authority
TW
Taiwan
Prior art keywords
cancer
tumor
seq
domain
diabody
Prior art date
Application number
TW105126154A
Other languages
English (en)
Chinese (zh)
Inventor
萊斯利 強生
保羅 摩爾
愛利歐 波維尼
玲 黃
坎帕納 尚
瑞夫 安德森
古蘭那達瑞迪 齊齊李
Original Assignee
宏觀基因股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 宏觀基因股份有限公司 filed Critical 宏觀基因股份有限公司
Publication of TW201718652A publication Critical patent/TW201718652A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW105126154A 2015-08-17 2016-08-16 能夠結合ｂ７－ｈ３和ｃｄ３的雙特異性單價雙抗體及其用途 TW201718652A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562206051P 2015-08-17 2015-08-17
US201662280318P 2016-01-19 2016-01-19

Publications (1)

Publication Number Publication Date
TW201718652A true TW201718652A (zh) 2017-06-01

Family

ID=58051498

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105126154A TW201718652A (zh) 2015-08-17 2016-08-16 能夠結合ｂ７－ｈ３和ｃｄ３的雙特異性單價雙抗體及其用途

Country Status (21)

Country Link
US (1) US20190002563A1 (enExample)
EP (1) EP3337507A4 (enExample)
JP (1) JP2018523686A (enExample)
KR (1) KR20180038045A (enExample)
CN (1) CN107921130A (enExample)
AU (1) AU2016307955A1 (enExample)
CA (1) CA2995709A1 (enExample)
CL (1) CL2018000422A1 (enExample)
CO (1) CO2018001485A2 (enExample)
CR (1) CR20180105A (enExample)
EA (1) EA201890443A1 (enExample)
EC (1) ECSP18011248A (enExample)
HK (1) HK1249423A1 (enExample)
IL (1) IL257562A (enExample)
MA (1) MA42665A (enExample)
MX (1) MX2018001954A (enExample)
PE (1) PE20181066A1 (enExample)
PH (1) PH12018500363A1 (enExample)
TW (1) TW201718652A (enExample)
WO (1) WO2017030926A1 (enExample)
ZA (1) ZA201800955B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI823811B (zh) * 2017-09-08 2023-11-21 日商武田藥品工業股份有限公司 限制性條件性活化之結合蛋白

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913680PA (en) * 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
AP2017009823A0 (en) 2014-09-26 2017-03-31 Macrogenics Inc Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof
JP6955507B2 (ja) 2015-12-14 2021-10-27 マクロジェニクス，インコーポレーテッド Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
JP7132232B2 (ja) 2017-02-24 2022-09-06 マクロジェニクス，インコーポレーテッド Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用
WO2018191438A1 (en) 2017-04-11 2018-10-18 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
CN109939230A (zh) * 2017-12-21 2019-06-28 张曼 关于cd3×b7h3双特异性抗体定向杀伤耐顺铂膀胱癌细胞t24/ddp的应用
CN109939231A (zh) * 2017-12-21 2019-06-28 张曼 关于cd3×b7h3双特异性抗体定向杀伤膀胱癌细胞t24的应用
CN109939126A (zh) * 2017-12-21 2019-06-28 张曼 Cd3×b7h3双特异抗体定向杀伤耐阿霉素膀胱癌细胞pumc-91/adm的应用
CN109939232A (zh) * 2017-12-21 2019-06-28 张曼 关于cd3×b7h3双特异性抗体定向杀伤膀胱癌细胞pumc-91的应用
CN109971711A (zh) * 2017-12-27 2019-07-05 张曼 关于cd3×b7h3双特异性抗体定向杀伤人膀胱癌细胞的应用
SG11202007572VA (en) * 2018-02-15 2020-09-29 Macrogenics Inc Variant cd3-binding domains and their use in combination therapies for the treatment of disease
IL277863B2 (en) 2018-04-11 2026-02-01 Inhibrx Inc Multispecific polypeptide constructs with forced CD3 binding and related methods and uses
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
CA3105891A1 (en) 2018-07-24 2020-01-30 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
CN109762068A (zh) * 2018-08-09 2019-05-17 源道隆（苏州）医学科技有限公司 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用
WO2020077257A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
CA3115082A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. B7h3 single domain antibodies and therapeutic compositions thereof
CN112969476B (zh) * 2018-12-07 2024-06-14 江苏恒瑞医药股份有限公司 多特异性蛋白分子
CN112955471B (zh) 2018-12-07 2022-11-22 江苏恒瑞医药股份有限公司 Cd3抗体及其药物用途
KR102732027B1 (ko) * 2019-07-09 2024-11-20 주식회사 와이바이오로직스 B7-h3(cd276)에 특이적으로 결합하는 항체 및 그의 용도
CN111454357B (zh) * 2019-08-14 2022-03-15 康诺亚生物医药科技（成都）有限公司 一种含有抗体的肿瘤治疗剂的开发和应用
EP3822288A1 (en) * 2019-11-18 2021-05-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
MX2022007790A (es) * 2019-12-23 2022-10-18 Macrogenics Inc Terapia para el tratamiento del cancer.
IL294879A (en) 2020-01-29 2022-09-01 Inhibrx Inc Monodomain antibodies of cd28 and their multivalent and multispecific constructs
CA3189590A1 (en) * 2020-07-17 2022-01-20 Pfizer Inc. Therapeutic antibodies and their uses
EP4032910A1 (en) * 2021-01-22 2022-07-27 ETH Zurich Bispecific binding agent that binds to cd3 and a fluorophore
US20240218069A1 (en) * 2021-04-28 2024-07-04 Lyvgen Biopharma Holdings Limited Bi-specific antibodies comprising anti-b7h3 binding molecules
CN113527493B (zh) * 2021-07-20 2023-10-27 广州爱思迈生物医药科技有限公司 一种b7-h3抗体及其应用
US20230151095A1 (en) 2021-11-12 2023-05-18 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
CN114539420B (zh) * 2022-01-20 2024-05-17 荣昌生物制药(烟台)股份有限公司 抗b7-h3单克隆抗体、抗b7-h3×cd3双特异性抗体、制备方法及其应用
CN117903311B (zh) * 2024-03-20 2024-10-25 湖南卓润生物科技有限公司 sST2特异性结合蛋白及其制备方法和应用
WO2025245264A1 (en) * 2024-05-21 2025-11-27 Briapro Therapeutics Corp. Anti-b7-h3 antibodies and methods of use thereof
WO2026008059A1 (en) * 2024-07-04 2026-01-08 Nanjing Legend Biotech Co., Ltd. Anti-dll3 constructs and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12018501083A1 (en) * 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US9587021B2 (en) * 2011-05-21 2017-03-07 Macrogenics, Inc. CD3-binding molecules capable of binding to human and non-human CD3
US10851178B2 (en) * 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US9487587B2 (en) * 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
UA116479C2 (uk) * 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2839842A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
CN108136010A (zh) * 2015-10-08 2018-06-08 宏观基因有限公司 用于治疗癌症的联合疗法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI823811B (zh) * 2017-09-08 2023-11-21 日商武田藥品工業股份有限公司 限制性條件性活化之結合蛋白

Also Published As

Publication number Publication date
KR20180038045A (ko) 2018-04-13
MX2018001954A (es) 2018-11-09
PH12018500363A1 (en) 2018-09-10
EP3337507A1 (en) 2018-06-27
CR20180105A (es) 2018-06-12
US20190002563A1 (en) 2019-01-03
CL2018000422A1 (es) 2018-08-10
IL257562A (en) 2018-04-30
WO2017030926A1 (en) 2017-02-23
EA201890443A1 (ru) 2018-09-28
AU2016307955A1 (en) 2018-03-08
JP2018523686A (ja) 2018-08-23
MA42665A (fr) 2018-06-27
CN107921130A (zh) 2018-04-17
ECSP18011248A (es) 2018-04-30
EP3337507A4 (en) 2019-04-24
CA2995709A1 (en) 2017-02-23
CO2018001485A2 (es) 2018-07-10
HK1249423A1 (zh) 2018-11-02
ZA201800955B (en) 2018-11-28
PE20181066A1 (es) 2018-07-04

Similar Documents

Publication Publication Date Title
US20190002563A1 (en) Bispecific Monovalent Diabodies That are Capable of Binding B7-H3 and CD3, and Uses Thereof
TWI788327B (zh) 能夠結合cd137和腫瘤抗原的雙特異性結合分子及其用途
TWI691509B (zh) Ｐｄ-１結合分子和其使用方法
EP3161004B1 (en) Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
TWI718098B (zh) 三特異性結合分子及其使用方法
AU2015321546B2 (en) Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof
TWI688572B (zh) 包含dr5-結合結構域的多價分子
JP2021525087A (ja) 抗ｐｖｒｉｇ／抗ｔｉｇｉｔ二重特異性抗体および使用方法
TW201742636A (zh) 聯合療法
TW201627322A (zh) 抗-ｄｒ５抗體和包括其ｄｒ５-結合結構域的分子
KR20180021786A (ko) Lag-3-결합 분자 및 그 사용 방법
TWI814758B (zh) 雙特異性ｃｄ１６-結合分子及其在疾病治療中的用途
JP2022120061A (ja) 炎症性疾患及び障害の治療におけるｃｄ３２ｂ×ｃｄ７９ｂ結合分子
TW202317624A (zh) 結合cldn18.2及cd3之雙特異性結合劑
JP2024520638A (ja) 抗ｉｃｏｓ抗体によるｐｄ－ｌ１陰性または低発現がんの処置
JP2023513515A (ja) 抗原ワクチン接種ならびにｐｄ－ｌ１およびｃｄ１３７に結合する結合剤を含む治療
JP7278623B2 (ja) 抗ｃｄ２７抗体およびその使用
CN118055950A (zh) 能够结合cd27的抗体、其变体及其用途
RU2805648C2 (ru) Биспецифические связывающие молекулы, способные связывать cd137 и опухолевые антигены, и варианты их применения
HK40069172B (zh) 包含三聚体tnf家族配体的抗原结合分子
HK40081055A (en) Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
HK1236976B (en) Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof